

# Carl R Blankart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/822438/publications.pdf>

Version: 2024-02-01

40  
papers

906  
citations

623734

14  
h-index

477307

29  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1406  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a telemonitoring intervention in patients with chronic heart failure in Germany: A difference-in-difference matching approach using real-world data. Journal of Telemedicine and Telecare, 2023, 29, 365-373.	2.7	5
2	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. Health Economics (United Kingdom), 2022, 31, 179-194.	1.7	6
3	How to pay primary care physicians for SARS-CoV-2 vaccinations: An analysis of 43 EU and OECD countries. Health Policy, 2022, 126, 485-492.	3.0	5
4	An approach to quantify parameter uncertainty in early assessment of novel health technologies. Health Economics (United Kingdom), 2022, , .	1.7	2
5	Regulatory and HTA early dialogues in medical devices. Health Policy, 2021, 125, 1322-1329.	3.0	8
6	Differences in health care spending and utilization among older frail adults in high-income countries: ICCONIC hip fracture persona. Health Services Research, 2021, 56, 1335-1346.	2.0	22
7	Within and across country variations in treatment of patients with heart failure and diabetes. Health Services Research, 2021, 56, 1358-1369.	2.0	5
8	International comparison of health spending and utilization among people with complex multimorbidity. Health Services Research, 2021, 56, 1317-1334.	2.0	24
9	Power Dynamics in Inter-organizational Strategizing. Proceedings - Academy of Management, 2021, 2021, 16247.	0.1	0
10	Differences in health outcomes for high-need high-cost patients across high-income countries. Health Services Research, 2021, 56 Suppl 3, 1347-1357.	2.0	13
11	International comparison of spending and utilization at the end of life for hip fracture patients. Health Services Research, 2021, 56, 1370-1382.	2.0	9
12	Improving health care from the bottom up: Factors for the successful implementation of kaizen in acute care hospitals. PLoS ONE, 2021, 16, e0257412.	2.5	2
13	An international comparison of long-term care trajectories and spending following hip fracture. Health Services Research, 2021, 56, 1383-1393.	2.0	10
14	A methodology for identifying high-need, high-cost patient personas for international comparisons. Health Services Research, 2021, 56, 1302-1316.	2.0	5
15	Validation and application of a needs-based segmentation tool for cross-country comparisons. Health Services Research, 2021, 56, 1394-1404.	2.0	3
16	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Frontiers in Public Health, 2020, 8, 612410.	2.7	9
17	Exploring Enablers of Open Strategy-Making in Cross-Sector Settings. Proceedings - Academy of Management, 2020, 2020, 12875.	0.1	0
18	How military history can inspire medical intervention. Cardiovascular Diagnosis and Therapy, 2020, 10, 2048-2053.	1.7	0

#	ARTICLE	IF	CITATIONS
19	The effect of political control on financial performance, structure, and outcomes of US nursing homes. <i>Health Services Research</i> , 2019, 54, 167-180.	2.0	3
20	Improving Service Provision - The Health Care Services' Perspective. <i>Journal of Service Management Research</i> , 2019, 3, 163-183.	0.3	4
21	Comparing the Efficiency of Hospitals in Italy and Germany: Nonparametric Conditional Approach Based on Partial Frontier. <i>Health Care Management Science</i> , 2017, 20, 379-394.	2.6	15
22	Preferred supplier contracts in post-patent prescription drug markets. <i>Health Care Management Science</i> , 2017, 20, 419-432.	2.6	5
23	The Role of Learning in Health Technology Assessments: An Empirical Assessment of Endovascular Aneurysm Repairs in German Hospitals. <i>Health Economics (United Kingdom)</i> , 2017, 26, 93-108.	1.7	17
24	The determinants of medical technology adoption in different decisional systems: A systematic literature review. <i>Health Policy</i> , 2017, 121, 230-242.	3.0	35
25	The PMA Scale: A Measure of Physicians's Motivation to Adopt Medical Devices. <i>Value in Health</i> , 2017, 20, 533-541.	0.3	15
26	Adoption Decisions for Medical Devices in the Field of Cardiology: Results from a European Survey. <i>Health Economics (United Kingdom)</i> , 2017, 26, 124-144.	1.7	21
27	I-SWOT as instrument to individually optimize therapy of thoracoabdominal aortic aneurysms. <i>Gefasschirurgie</i> , 2017, 22, 8-16.	0.7	1
28	Using nonparametric conditional approach to integrate quality into efficiency analysis: empirical evidence from cardiology departments. <i>Health Care Management Science</i> , 2017, 20, 565-576.	2.6	13
29	The Effect of Political Control on Financial Performance and Structure of US Nursing Homes.. <i>Proceedings - Academy of Management</i> , 2017, 2017, 15710.	0.1	0
30	Characteristics of Patients Dying With Cancer in Developed Countries"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2732.	7.4	0
31	The Health Care Strengthening Act: The next level of integrated care in Germany. <i>Health Policy</i> , 2016, 120, 445-451.	3.0	31
32	Economic and care considerations of Marfan syndrome. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 591-598.	1.4	7
33	Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 272.	7.4	388
34	Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. <i>Pharmacoeconomics</i> , 2016, 34, 479-498.	3.3	23
35	HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES: A SURVEY OF NON-EUROPEAN UNION AGENCIES. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 154-165.	0.5	49
36	The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 90.	2.7	17

#	ARTICLE	IF	CITATIONS
37	Cost of illness and economic burden of chronic lymphocytic leukemia. Orphanet Journal of Rare Diseases, 2013, 8, 32.	2.7	28
38	Does healthcare infrastructure have an impact on delay in diagnosis and survival?. Health Policy, 2012, 105, 128-137.	3.0	26
39	Availability of and Access to Orphan Drugs. Pharmacoeconomics, 2011, 29, 63-82.	3.3	69
40	Der Spendenmultiplikator. WiSt - Wirtschaftswissenschaftliches Studium, 2002, 31, 465-466.	0.0	0